MET inhibition radiosensitizes KRAS-mutant rectal cancer.

被引：0

作者：

D'Ambrosio, Antonio ^{[1
]}

Verginelli, Federica ^{[1
]}

Orzan, Francesca ^{[1
]}

Albano, Raffaella ^{[1
]}

Casanova, Elena ^{[1
]}

Luraghi, Paolo ^{[1
]}

De Bacco, Francesca ^{[1
]}

Bertotti, Andrea ^{[2
]}

Trusolino, Livio ^{[2
]}

Senetta, Rebecca ^{[3
]}

Sapino, Anna ^{[3
]}

Del Mastro, Elena ^{[4
]}

Gatti, Marco ^{[4
]}

Comoglio, Paolo M. ^{[5
]}

Boccaccio, Carla ^{[1
]}

机构：

[1] IRCCS Candiolo Canc Inst, Lab Canc Stem Cell Res FPO, Candiolo, Italy

[2] IRCCS Candiolo Canc Inst, Lab Translat Canc Med FPO, Candiolo, Italy

[3] IRCCS Candiolo Canc Inst, Unit Pathol FPO, Candiolo, Italy

[4] IRCCS Candiolo Canc Inst, Unit Radiotherapy FPO, Candiolo, Italy

[5] IRCCS Candiolo Canc Inst, Lab Exploratory Res & Mol Canc Therapy FPO, Candiolo, Italy

来源：

CANCER RESEARCH | 2021年 / 81卷 / 13期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1387

引用

页数：2

共 50 条

[31] Efficacy of BET Bromodomain Inhibition in Kras-Mutant Non-Small Cell Lung Cancer
Shimamura, Takeshi
Chen, Zhao
Soucheray, Margaret
Carretero, Julian
Kikuchi, Eiki
Tchaicha, Jeremy H.
Gao, Yandi
Cheng, Katherine A.
Cohoon, Travis J.
Qi, Jun
Akbay, Esra
Kimmelman, Alec C.
Kung, Andrew L.
Bradner, James E.
Wong, Kwok-Kin
CLINICAL CANCER RESEARCH, 2013, 19 (22) : 6183 - 6192
[32] Temporal inhibition of ERK is sufficient for tumor growth inhibition in KRAS-mutant or BRAF-mutant tumors
Bhagwat, Shripad V.
Shen, Weihua
Zhao, Baohui
Cai, Shufen
Kindler, Lisa
McMillen, William T.
Yuen, Eunice
McCann, Denis
Manro, Jason
Dropsey, Andrew J.
Willard, Melinda D.
Joseph, Sajan
Peng, Sheng-Bin
CANCER RESEARCH, 2020, 80 (16)
[33] Coadministration of Trametinib and Palbociclib Radiosensitizes KRAS-Mutant Non-Small Cell Lung Cancers In Vitro and In Vivo
Tao, Zhen
Le Blanc, Justin M.
Wang, Chenguang
Zhan, Tingting
Zhuang, Hongqing
Wang, Ping
Yuan, Zhiyong
Lu, Bo
CLINICAL CANCER RESEARCH, 2016, 22 (01) : 122 - 133
[34] Dasatinib sensitizes KRAS-mutant colorectal cancer tumors to cetuximab
Lisa Hutchinson
Nature Reviews Clinical Oncology, 2011, 8 (4) : 193 - 193
[35] A novel combination strategy to treat KRAS-mutant lung cancer
Peng, R. -W.
Liang, S. -Q.
Buhrer, E. D.
Berezowska, S.
Marti, T. M.
Froment, L.
Yang, H.
Hall, S. R.
Vassella, E.
Yang, Z.
Kocher, G. J.
Amrein, M. J.
Riether, C.
Ochsenbein, A. F.
Schmid, R. A.
BRITISH JOURNAL OF SURGERY, 2019, 106 : 19 - 19
[36] Sotorasib effective in KRAS-mutant NSCLC
Sidaway, Peter
NATURE REVIEWS CLINICAL ONCOLOGY, 2021, 18 (08) : 470 - 470
[37] Immunogenic chemotherapy effectively constrains KRAS-mutant lung cancer
Wang, D.
Cong, J.
Fu, B.
Zheng, X.
Sun, R.
Tian, Z.
Wei, H.
EUROPEAN JOURNAL OF IMMUNOLOGY, 2019, 49 : 1893 - 1893
[38] Novel agents for KRAS-mutant NSCLC
Janne, Pasi A.
ANNALS OF ONCOLOGY, 2022, 33 : S444 - S444
[39] Correction: Suppression of interferon gene expression overcomes resistance to MEK inhibition in KRAS-mutant colorectal cancer
Steve Wagner
Georgios Vlachogiannis
Alexis De Haven Brandon
Melanie Valenti
Gary Box
Liam Jenkins
Caterina Mancusi
Annette Self
Floriana Manodoro
Ioannis Assiotis
Penny Robinson
Ritika Chauhan
Alistair G. Rust
Nik Matthews
Kate Eason
Khurum Khan
Naureen Starling
David Cunningham
Anguraj Sadanandam
Clare M. Isacke
Vladimir Kirkin
Nicola Valeri
Steven R. Whittaker
Oncogene, 2019, 38 : 5746 - 5746
[40] Focal Adhesion Kinase Regulates the DNA Damage Response and Its Inhibition Radiosensitizes Mutant KRAS Lung Cancer
Tang, Ke-Jing
Constanzo, Jerfiz D.
Venkateswaran, Niranjan
Melegari, Margherita
Ilcheva, Mariya
Morales, Julio C.
Skoulidis, Ferdinandos
Heymach, John V.
Boothman, David A.
Scaglioni, Pier Paolo
CLINICAL CANCER RESEARCH, 2016, 22 (23) : 5851 - 5863

← 1 2 3 4 5 →